Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief Legal Officer | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 400,703 |
Ending reported balance
After 2026-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Exercise / conversion · Acquired 62,500 · Balance 463,203 F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Row 2 · 2026-05-13 · Sale · Disposed 62,500 · Balance 400,703 F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2027-12-20 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-13 · Exercise / conversion · Disposed 62,500 · Balance 0 F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
F2: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 15, 2026 20:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000882796-26-000021 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2027-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 62,500 | $9.54 | $596,250.00 |
DisclosureSEC source: 0000882796-26-000021 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,703 F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 62,500 | $5.04 | $315,000.00 |
DisclosureSEC source: 0000882796-26-000021 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000882796-26-000015 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F3 · derivative.exercise_date: The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 150,000 | $9.15 | $1,372,500.00 |
DisclosureSEC source: 0000882796-26-000015 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,703 F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 150,000 | $5.51 | $826,500.00 |
DisclosureSEC source: 0000882796-26-000015 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 550,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 21,773 | $7.65 | $166,563.45 |
DisclosureSEC source: 0000882796-25-000043 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,751 F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 16,902 | $7.41 | $125,243.82 |
DisclosureSEC source: 0000882796-25-000043 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 420,524 F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:17 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 255,050 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001171843-25-008037 · ownership.xml · derivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,050 Underlying: Common Stock · 255,050 shares Expires 2035-12-17 F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:17 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 121,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-008037 · ownership.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,426 F1 · shares: Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 21,210 | $7.65 | $162,256.50 |
DisclosureSEC source: 0000882796-25-000033 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,726 F2 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 8,540 | $7.57 | $64,647.80 |
DisclosureSEC source: 0000882796-25-000033 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,936 F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person. Read SEC document |
| December 03, 2025 Filed Dec 3, 2025 23:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 19,770 | $7.65 | $151,240.50 |
DisclosureSEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 4 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,476 F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 23:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 50,906 | $7.21 | $367,215.52 |
DisclosureSEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 3 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 365,246 F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.180 to $7.255. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 23:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 91,004 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000882796-25-000027 · form4.xml · derivative · entry 5 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,004 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F4 · derivative.exercise_date: The option grant became exercisable at the rate of 25.0% on each of the first, second, third, and fourth anniversaries of the date of grant. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 23:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 91,004 | $7.10 | $646,510.62 |
DisclosureSEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,152 F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.015 to $7.190. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 23:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 91,004 | $3.22 | $293,032.88 |
DisclosureSEC source: 0000882796-25-000027 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 507,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 250,100 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001127602-24-029952 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,100 Underlying: Common Stock · 250,100 shares Expires 2034-12-19 F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 2,461 | $7.39 | $18,186.79 |
DisclosureSEC source: 0001127602-24-029952 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,729 F2 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 120,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-029952 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,190 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2024 Filed Dec 17, 2024 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 8,613 | $7.53 | $64,855.89 |
DisclosureSEC source: 0001127602-24-029582 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,490 F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. Read SEC document |
| May 13, 2024 Filed May 15, 2024 11:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 5,000 | $5.53 | $27,650.00 |
DisclosureSEC source: 0001127602-24-015367 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,762 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.36 to $5.64. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 2,482 | $6.05 | $15,016.10 |
DisclosureSEC source: 0001127602-23-030177 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,539 F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 158,500 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0001127602-23-029829 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,500 Underlying: Common Stock · 158,500 shares Expires 2033-12-14 F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 4,015 | $6.43 | $25,816.45 |
DisclosureSEC source: 0001127602-23-029829 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,021 F2 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:34 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 64,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029829 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,036 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 158,500 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0001127602-22-028084 · form4.xml · derivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,500 Underlying: Common Stock · 158,500 shares Expires 2032-12-19 F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-028084 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,770 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 4,175 | $10.88 | $45,424.00 |
DisclosureSEC source: 0001127602-22-027858 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,770 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 13,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 164,000 | $0.00 Strike: $11.43 | $0.00 |
DisclosureSEC source: 0001127602-21-031126 · form4.xml · derivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2031-12-14 F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031126 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,969 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Jan 13, 2022 21:36 UTC Amendment | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001452 · form4a.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,969 F1 · shares: The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error. This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 35,852 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · derivative · entry 9 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,852 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 35,852 | $4.73 | $169,579.96 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 5 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 68,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · derivative · entry 8 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,000 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested upon the achievement of performance-based vesting criteria with respect to 17,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 33,132 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · derivative · entry 7 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,132 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 1,648 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · derivative · entry 6 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Common Stock · 1,648 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 102,780 | $12.04 | $1,237,471.20 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 4 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,275 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.00 to $12.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 68,000 | $5.45 | $370,600.00 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 3 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 33,132 | $1.42 | $47,047.44 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:43 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 1,648 | $4.73 | $7,795.04 |
DisclosureSEC source: 0001127602-21-016587 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-20-031791 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2030-12-15 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 13,741 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001127602-20-031406 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,741 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 13,741 | $7.96 | $109,378.36 |
DisclosureSEC source: 0001127602-20-031406 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,061 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.97. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 22:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 13,741 | $4.15 | $57,025.15 |
DisclosureSEC source: 0001127602-20-031406 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 13,741 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001127602-20-030837 · form4.xml · derivative · entry 3 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,741 Underlying: Common Stock · 13,741 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 13,741 | $6.23 | $85,606.43 |
DisclosureSEC source: 0001127602-20-030837 · form4.xml · nonDerivative · entry 2 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,061 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.22 to $6.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:12 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 13,741 | $4.15 | $57,025.15 |
DisclosureSEC source: 0001127602-20-030837 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-20-030700 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2023-08-08 F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:44 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 12,400 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007677 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Underlying: Common Stock · 12,400 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.